Pharmacogenomics and personalized medicine: Mapping of future value creation

BioTechniques

Volumn 39, Issue , 2005, Pages 6-

  Hu, Sean Xinghua ^a   Foster, Thomas ^a   Kieffaber, Ann ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG INDUSTRY; ECONOMIC ASPECT; GENOMICS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH SERVICE; HUMAN; MARKETING; MOLECULAR DIAGNOSIS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; DRUG EFFECTS; FORECASTING; GENETIC VARIABILITY; PHARMACOGENETICS; PHYSIOLOGY; PROCEDURES; TRENDS;

DRUG;

FORECASTING; GENETIC VARIATION; HEALTH CARE SECTOR; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 84953723083     PISSN: 07366205     EISSN: 19409818     Source Type: Journal    
DOI: 10.2144/000112048     Document Type: Article

References (5)

1. RBC Capital Markets. 2003. Equity research report, The In-Vitro Diagnostics Industry, Dec. 5th, 2003.
2. Robert W. Baird & Co. 2003. Equity research report on Beckman Coulter, Inc., Sept. 23rd, 2003.
3. Lagay, F. 2003. Pharmacogenomics: revolution in a bottle? American Medical Association; http://www. ama-assn. org/ama/pub/category/7459. html.
4. Ingelman-Sundberg, M. 2001. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250: 186.
5. Lander, E., B. Austin, J. Peterson, and J. Schloss. 2002. Sequencing and re-sequencing the biome! National Human Genome Research Institute; www. genome. gov/10005564.